Tagged with S

AstraZeneca Hungary The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in Hungary? I would say that it has become an extremely difficult environment to operate in. There is a myth that…

Janssen Pharmaceutical Hungary Hungary is one of the largest pharmaceutical markets in the region, and has been used by Janssen-Cilag as a hub. Can you elaborate on how important Hungary is for Janssen-Cilag within the CEE region today? It is not the easiest question, as Hungary’s importance is changing from year to year.…

Sanofi-Aventis Hungary Sanofi for 3,5 years. It must have been quite a different market, culture and environment. Yet, at that time you publicly announced that it only took you 30 seconds to accept the move. Why was this such an easy choice? In Hungary, Sanofi has a presence that reaches far beyond…

Russia CONSULTING You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind the creation of Russia Consulting, and the main growth drivers contributing to its development? When I was a student, I…

Quintiles Russia The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations Russia Quintiles very recently announced the launch of its first commercial project in Russia, after setting up a local legal entity for the delivery of commercial operations. What is the nature of this…

Quintiles Russia The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and Operations, CEE, CIS and Russia Quintiles very recently announced the launch of its first commercial project in Russia, after setting up a local legal entity for the delivery of commercial operations. What…

EGIS Romania You have been general manager of this affiliate for three years after a previous tenure as general manager of Leo Pharma here and in Bulgaria. The end of 2008 through 2010 were certainly not the easiest years for pharmaceutical companies. What was the business environment like when you first came…

GSK Pharma CIS GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s portfolio into novel areas and putting greater emphasis on emerging markets. How is the Russian affiliate contributing to the realization…

Goltsblat BLP Pepeliaev, Goltsblat & Partners and the major UK firm Berwin Leighton Paisner (BLP). It calls itself the first international Russian law firm. Can you explain to our readers the rationale behind the creation of this firm and why Goltsblat BLP is interesting for the market? There was a split amongst…

Pharmstandard You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the company developed since the IPO? We were honored on the London Stock Exchange as the Best Newcomer of 2007, and…

Galderma Laboratories Russia You were working for GSK since 2003 before joining Galderma this year. Some within the industry might view Galderma as a step down from the third-ranked pharmaceutical company in the world. What convinced you to take this position? I would certainly not call my transition to Galderma a step down!…

Actavis Romania We understand that you already took over the reins at Actavis as interim GM in late 2009, before being officially appointed a few months later in 2010. What have been the key milestones and achievements of Actavis in Romania since then? In fact, I took the position as General Manager…